ACE inhibition is renoprotective among obese patients with proteinuria

Journal of the American Society of Nephrology

Volumn 22, Issue 6, 2011, Pages 1122-1128

  Mallamaci, Francesca ^a   Ruggenenti, Piero ^b   Perna, Annalisa ^b   Leonardis, Daniela ^a   Tripepi, Rocco ^a   Tripepi, Giovanni ^a   Remuzzi, Giuseppe ^b   Zoccali, Carmine ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN; RAMIPRIL;

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBESITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT RESPONSE;

EID: 79957775948     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010090969     Document Type: Article

References (21)

1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH: The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 9: 88, 2009
2. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65: 1870-1876, 2004
3. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 144: 21-28, 2006 (Pubitemid 46780716)
4. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O: Obesity and risk for chronic renal failure. J Am Soc Nephrol 17: 1695-1702, 2006 (Pubitemid 43794672)
5. Elsayed EF, Sarnak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, Levey AS, Weiner DE: Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 52: 29-38, 2008 (Pubitemid 351853273)
6. Ritz E: Obesity and CKD: How to assess the risk? Am J Kidney Dis 52: 1-6, 2008
7. Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G: Body mass index is associated with altered renal hemodynamics in nonobese healthy subjects. Kidney Int 65: 259-265, 2004 (Pubitemid 38037512)
8. McClellan WM: The epidemic of renal disease: What drives it and what can be done? Nephrol Dial Transplant 21: 1461-1464, 2006
9. Wahba IM, Mak RH: Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2: 550-562, 2007
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349: 1857-1863, 1997
11. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S: Weight loss interventions in chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 4: 1565-1574, 2009
12. Bosma RJ, Krikken JA, Homan van der Heide JJ, de Jong PE, Navis GJ: Obesity and renal hemodynamics. Contrib Nephrol 151: 184-202, 2006 (Pubitemid 44298232)
13. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304: 930-933, 1981 (Pubitemid 11101080)
14. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45: 356-362, 2005 (Pubitemid 40315803)
15. Sowers JR, Whitfield LA, Catania RA, Stern N, Tuck ML, Dornfeld L, Maxwell M: Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 54: 1181-1186, 1982 (Pubitemid 13238698)
16. Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, Guerrieri M, Mantero F: Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 15: 381-388, 2002 (Pubitemid 34478475)
17. Ruster C, Wolf G: Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17: 2985-2991, 2006 (Pubitemid 44707758)
18. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T: Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724, 2006 (Pubitemid 44684802)
19. Mathieu C, Teta D, Vogt B, Burnier M: [Obesity: what impact on renal function?] Rev Med Suisse 2: 576-581, 2006
20. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM: Statistics in medicine: Reporting of subgroup analyses in clinical trials. N Engl J Med 357: 2189-2194, 2007
21. Kleinbaum DG, Klein M: Survival Analysis. A Self Learning Text, 2nd ed., New York, Springer, 2005